Epileptic
seizures are a common feature associated with inherited
mitochondrial diseases. This study investigated the role of mitochondrial oxidative stress in
epilepsy resulting from
mitochondrial dysfunction using cross-bred mutant mice lacking mitochondrial
manganese superoxide dismutase (MnSOD or SOD2) and a lipophilic
metalloporphyrin catalytic
antioxidant. Video-EEG monitoring revealed that in the second to third week of postnatal life (P14-P21) B6D2F2 Sod2(-/-) mice exhibited frequent spontaneous
motor seizures providing evidence that oxidative stress-induced
mitochondrial dysfunction may contribute to epileptic
seizures. To confirm the role of mitochondrial oxidative stress in
epilepsy a newly developed lipophilic
metalloporphyrin,
AEOL 11207, with high potency for catalytic removal of endogenously generated
reactive oxygen species was utilized. AEOL 11207-treated Sod2(-/-) mice showed a significant decrease in both the frequency and duration of spontaneous
seizures but no effect on seizure severity. A significant increase in the average lifespan of AEOL 11207-treated Sod2(-/-) mice compared to vehicle-treated Sod2(-/-) mice was also observed. Indices of mitochondrial oxidative stress and damage (
aconitase inactivation, 3-
nitrotyrosine formation, and depletion of reduced
coenzyme A) and
ATP levels affecting neuronal excitability were significantly attenuated in the brains of AEOL 11207-treated Sod2(-/-) mice compared to vehicle-treated Sod2(-/-) mice. The occurrence of epileptic
seizures in Sod2(-/-) mice and the ability of catalytic
antioxidant therapy to attenuate seizure activity,
mitochondrial dysfunction, and
ATP levels suggest that ongoing mitochondrial oxidative stress can contribute to
epilepsy associated with
mitochondrial dysfunction and disease.